Hyperfine (NASDAQ:HYPR) Announces Quarterly Earnings Results

Hyperfine (NASDAQ:HYPR) posted its quarterly earnings results on Monday. The company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.02, FiscalAI reports. Hyperfine had a negative net margin of 210.75% and a negative return on equity of 97.88%. The firm had revenue of $5.96 million during the quarter, compared to the consensus estimate of $5.84 million.

Here are the key takeaways from Hyperfine’s conference call:

• Hyperfine reported a record $6.0 million in Q3 revenue, up 73% year over year, with contributions from U.S. hospitals, U.S. offices, and international markets. Gross margin reached a record 56.7%, and revenue grew much faster than operating expenses.
• Operating leverage improved: operating loss narrowed to $7.3 million, while net cash burn fell 29% sequentially to a quarterly low of $5.6 million—below quarterly revenue for the first time. The company ended September with $37.9 million in cash and expects runway into 2028, assuming no additional financing or future debt draws.
• Management reaffirmed 2026 revenue guidance of $20 million–$22 million and net cash burn guidance of $26 million–$28 million, while raising the low end of its gross-margin range to 52.5% from 50%. The revenue outlook was not raised despite the strong quarter; management cited the lumpy nature of capital-equipment sales and a one-time system upgrade that boosted Q4 2025 revenue.
• The company completed enrollment in its Contrast PMR study and remains on track to submit a 510(k) application by year-end 2026; management said clearance could come around Q2 to mid-2027. It expects contrast imaging to broaden use in hospitals and offices, including access to a dedicated reimbursement code in outpatient settings.
• Hyperfine is exploring a brain-health and wellness offering using its existing scanner, with potential software and cloud development rather than major hardware changes. Management characterized this as an emerging opportunity, but does not expect meaningful revenue from it before 2028 or later.

Hyperfine Stock Down 1.3%

HYPR stock traded down $0.01 during midday trading on Monday, reaching $0.71. 417,647 shares of the company’s stock traded hands, compared to its average volume of 731,356. The company has a quick ratio of 5.45, a current ratio of 6.15 and a debt-to-equity ratio of 0.36. The firm’s fifty day moving average price is $0.80 and its 200-day moving average price is $1.11. Hyperfine has a 52 week low of $0.67 and a 52 week high of $1.94. The company has a market cap of $75.29 million, a price-to-earnings ratio of -1.87 and a beta of 1.49.

Analyst Ratings Changes

HYPR has been the topic of a number of research analyst reports. Loop Capital set a $2.00 price objective on shares of Hyperfine in a research report on Tuesday, October 27th. BTIG Research reaffirmed a “buy” rating and issued a $2.00 target price on shares of Hyperfine in a research report on Tuesday, September 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Hyperfine in a research note on Thursday, October 15th. Wall Street Zen lowered Hyperfine from a “hold” rating to a “sell” rating in a report on Sunday. Finally, Lucid Cap Mkts assumed coverage on Hyperfine in a report on Tuesday, October 27th. They issued a “strong-buy” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Hyperfine currently has a consensus rating of “Moderate Buy” and a consensus target price of $2.02.

About Hyperfine

Hyperfine, Inc (NASDAQ: HYPR) is a medical technology company focused on making magnetic resonance imaging more accessible and convenient. The company develops portable, low-field MRI technology designed to bring brain imaging directly to patients in locations such as intensive care units, emergency departments, operating rooms and other point-of-care settings.

Hyperfine’s primary product is the Swoop Portable MR Imaging System, a compact MRI platform that can be moved to a patient’s bedside.